

Analysis of Allergic Rhinitis Using Machine Learning

Name: Sadia Afrose, ID: 21-45820-3, Section: B

Statement of Purpose

Allergic rhinitis (AR) is a condition that has very much affected my daily life, therefore making even little chores hard. Being an individual who has AR myself, I get the problems it causes fatigue, runny nose, nasal congestion, and incessant sneezing. Although drugs offer only temporary relief, they are not always successful and there is no lasting cure for this disorder. Inspired by this ongoing battle, I have started to study this area to help not only me but also to add to a more general knowledge that could benefit many more people dealing with the same issues.

As advanced as medicine is now, there is still no clear cure for AR, which is a chronic disease. Although all patients do not respond similarly, present therapies like antihistamines, steroids, and immunotherapy provide different types of symptom relief to the patients. I have found times when drugs just don't help, therefore I must live with the symptoms without respite. This lack of predictability has driven me to investigate different methods of machine learning improving diagnosis, therapy, and maybe unknown ideas that might result in better management strategies.

Already in medical research machine learning has exhibited potential by assisting in analyzing huge amounts of data, spotting patterns, and enhancing the accuracy of diagnosis. Machine learning technology provides each person's treatment and medication can be managed by their specific needs. This technology can further help us understand the environmental triggers that activate AR in people.

My aim is to gain a cure by machine learning which can make AR a curable disease and make life easy. It would be a major advancement toward improved quality of life for individuals with AR if technology could assist with disease control and perhaps even a breakthrough. By means of this study, I want to help the science society in their search for better treatments and, someday, maybe a cure for AR.

Research Proposal

Introduction

Allergies represent chronic inflammatory illnesses that produce incorrect immune responses to environmental substances named allergens. Proteins obtained from various sources act as allergens that trigger allergic reactions throughout different environmental spaces [1]. Patients are more likely to suffer from a typical cold than from AR because the standard diagnostic techniques are inconsistent and therefore physicians frequently fail to both identify and treat the condition correctly.

Chronic diseases represent the principal healthcare problem in the world today according to World Health Organization (WHO) data from 2002 that indicates these conditions contribute to 43% of global diseases (this number is projected to rise to 60% by the year 2020) [2]. Several personal and environmental elements showed a correlation with asthma and rhinitis as well as eczema development in population studies according to researchers [3]. Pediatric allergic diseases represent complex disorders that exist as multiple different medical conditions that closely affect one another. The increasing collection of big (bio)medical data together with the complexity of pediatric allergies makes this field an apt setting for AI-driven research activities. The widespread nature of pediatric allergies makes it likely for the public to benefit from AI-assisted clinical tools and allergen-prevention strategies in medical practice [4].

Literature Review

In allergic rhinitis diagnosis, ensemble learning can organically combine multiple prediction results obtained by multiple single learning models to obtain more accurate, stable, and strong results [5]. The creation of a model to perform binary classification on a given subject was the first objective of the model with a high macro F1 score and accuracy. The SVM model was intended to be used to determine which genes influence the onset of allergic rhinitis, as well as the weight of these genes. [6]. The emergence of AR shows a connection to mutant gene forms, 13–15 whereas vital roles in seasonal allergic rhinitis (SAR) rely on three genes of FOS, JUN, and CEBPD that connect. Research demonstrates that the pathogenesis of AR involves three genes namely CDC42EP5 and SLC39A11 and PRDM10 when studying seven samples from SAR patients and five samples from non-allergic patients [7].

The recognition of a user's specific gestures by a computational system and the triggering of a variety of events are considered extremely important and can lead to the development of many context-aware, wide-ranging applications. The possibility of developing Health-related mobile applications and Mobile Crowd Sensing systems (MCS) is also enabled, which can track users' activities to provide monitoring feedback and advice with respect to decision-making related to various diseases [8].

Novel research established a method to use wrist-worn devices combined with gesture recognition techniques for classifying gestures linked to allergic rhinitis symptoms [9].

On the other hand, it was proposed by a few authors to assess severe AR by analyzing patients in clusters and stratifying them based on the severity of their symptoms. Therefore, in literature, severe forms may be identified through physicians' questionnaires, self-assessment methods, or by analyzing the results of published cluster analysis [10]. The effect of microbial diversity on allergic diseases appears to be either beneficial or detrimental based on study findings. Libraries revealed that *Staphylococcus* nasal levels in asthmatic respiratory extracts were substantially greater than in healthy subjects leading to inflammatory factor release from human nasal epithelial cells thus worsening Th2 inflammatory responses. The researchers used 16S rRNA sequencing to determine the bacterial makeup of AR patients and healthy volunteer nasal airways to understand how these microbes participate in AR progression. Non-targeted metabolomics was used to study the differential metabolic status of AR patients and healthy volunteers to reveal both metabolic characteristics and understand the disease pathogenesis through multi-omics associations [11,12].

Symptomatic relief through existing diagnostic and treatment methods does not deliver extended allergy-free benefits to patients. The medical community performs new studies together with investigations to identify solutions for allergy treatment. Extensive information about allergens and allergies was made possible through the development of proteomic and genomic and analytical techniques. Bioinformatics experts face substantial challenges when trying to analyze and save the extensive databases that exist in allergens. Bioinformatics tools and resources serve as the key mechanism for dealing with this challenge [5]. In addition to having light shed on the roles of circulating miRNAs in the molecular pathogenesis of asthma and AR, potential significance in the diagnosis and management of these diseases has been established in the study and offering non-invasive diagnostic options [13].

Microbiological surveys conducted indoors and within environmental settings enable researchers to compile more beneficial microbial organisms for assessing substrate-microorganism pairings. These microorganisms together with their substrates present the potential to be employed inside buildings for managing allergic rhinitis symptoms [3]. Active smoking results in reduced FeNO levels while older age, male sex, and increased height and atopic condition correlate with elevated FeNO levels. Allergic disease risks in children depend on both their genetic inheritance together with shared environment and the allergic disease activity of their parents [14].

Scientists have studied different types of medications which treat allergic rhinitis. Major published studies assessed intranasal antihistamines and corticosteroids while demonstrating their benefits but also exposed patient compliance challenges [15, 16]. The measurement of nasal FENO is a useful method for the follow-up of patients with AR, especially in patients with PER. Physicians may be helped by nasal FENO measurement to estimate the level of response to treatment in patients with AR [17]. It has been shown by this study that Aze 0.15% is safe with long-term use over 12 months and that RQLQ is improved at 3, 6, 9, and 12 months similarly to MF, in improving quality of life scores [18].

Biologic agents are usually considered as a last-line therapy for EoE in patients refractory to dietary elimination, PPI, and oral topical steroids, and one of the reasons is probably related to the economic costs [19]. The blood count of eosinophil cells showed different results among patients diagnosed with various types of rhinitis. Subjects who showed elevated blood eosinophil counts developed worse nasal and eye symptoms and these individuals mostly had asthma or allergic conjunctivitis and not the other conditions. Research showed that allergic exposure levels created a positive relationship between both systemic and local eosinophil counts[20].

Objective

Main Objective

The objective is to evaluate AI-based models that enhance disease diagnostics and genetic factor detection and enable the search for potential therapies to address AR problems with finding cures.

Sub Objectives

1. AI-driven models analyze their performance in improving the accuracy and efficiency of diagnosis and enhance key genetic and environmental risk factors of AR.
2. The use of AI-driven bioinformatics and machine learning approaches along with researchers allows the identification of new AR treatment pathways to discover a final cure.

Research Question

Main Research Question

How AI-based models and their potential for disease diagnostics genetic factor detection and therapeutic search development offer solutions to tackle allergic rhinitis (AR) and its cure?

Sub Research Questions

1. What is the diagnostic performance level achieved by AI-driven models for allergic rhinitis when they detect genetic and environmental risk elements?
2. How bioinformatics systems and machine learning approaches can discover AR treatment methods for developing medical cures?

Research Methodology

The research goals will be investigated through an integrated use of computational methods together with bioinformatics and experimental techniques. This methodology set ensures systematic evaluation of AI technology

in diagnosing allergic rhinitis (AR) detecting genetic components and environmental elements and discovering new therapeutic methods.

AI-based model benefits for AR disease diagnosis alongside genetic risk determination and therapeutic search discovery will be studied through mixed research methods. Research will develop Support Vector Machines (SVM) and Random Forest and Deep Learning machine learning models through the evaluation of medical databases and patient records as well as genetic data and environmental exposure factors. To evaluate their performance the models will be tested according to their diagnostic accuracy through combination tests of sensitivity and specificity and F1-score assessments. Bioinformatics technologies will analyze genetic markers and environmental influence factors through which patterns regarding AR development and progression will be identified. Research investigators will evaluate the impact of AI technologies on diagnosis and treatment with a meta-analysis of published studies and a literature review method. Interview data from experienced allergists and geneticists together with AI researchers will deliver direct field evidence to validate the AI models. The selected methodology establishes a comprehensive assessment framework to understand both artificial intelligence's diagnostic capabilities for AR as well as innovative therapeutic measures.

The response requires a combination of computational analysis and experimental implementation to examine the diagnostic capabilities of AI-driven models to detect inheritable and environmental risk elements. The investigation will start with information collection and processing where doctors' records together with genetic markers alongside environmental exposure information will be retrieved from medical databases and scientific research. The data processing techniques will enforce high-quality model input by applying cleaning and standardization methods. The supervised learning algorithms of Decision Trees and SVM and Neural Networks require labeled datasets for training purposes to determine AR diagnosis probabilities from genetic information together with environmental factors. The most important factors that affect AR diagnosis identification will be determined through feature selection methods. The trained models will undergo performance evaluation through cross-validation which merges accuracy tests with precision testing recall evaluation and F1-score evaluation for reliability purposes. A research design will use statistical tests for significance to evaluate diagnostic models against traditional techniques by conducting a comparative assessment followed by accuracy benchmarking of clinical assessments and laboratory testing protocols. A real-world validation process using patients' unfamiliar data sets will be completed before medical professionals evaluate the AI-generated diagnostic information for its appropriate clinical use. This research approach will create an in-depth investigation of AI's enhancement capabilities for AR diagnosis effectiveness.

Discovering new treatments for AR through bioinformatics and machine learning methods will use computational biology and predictive modeling methodology. Obtainment of genomic and proteomic datasets about AR will happen through access to public data sources including NCBI and EMBL-EBI. AI-generated bioinformatics platforms will evaluate these datasets to find gene networks and protein relational patterns responsible for causing AR disease. The training of machine learning models will run simultaneously with existing AR treatment analysis to discover new potential drug applications. Deep learning for drug discovery will mimic medication development by examining molecular properties and their activity attached to AR. Using molecular docking techniques that simulate the interaction between pertinent proteins and found substances, in silico simulations combined will help to validate the usefulness of AI-generated medication forecasts. The research outcomes will receive validation through comparison against clinical trials as well as published studies to confirm their accuracy. The analysis will treat ethical aspects such as data privacy along with AI bias problems while suggesting opportunities for future AI use in AR therapy development. The method delivers systematic data-directed procedures that enable the identification of fresh AR treatments alongside potential medical remedies.

References

- [1] Aldakheel, F. M. (2021). Allergic Diseases: A Comprehensive Review on Risk Factors, Immunological Mechanisms, Link with COVID-19, Potential Treatments, and Role of Allergen Bioinformatics. *International Journal of Environmental Research and Public Health*, 18(22), 12105. <https://doi.org/10.3390/ijerph182212105>

- [2] Demoly, P., Bossé, I., & Maigret, P. (2020). Perception and control of allergic rhinitis in primary care. *Npj Primary Care Respiratory Medicine*, 30(1). <https://doi.org/10.1038/s41533-020-00195-8>
- [3] Fu, X., Ou, Z., & Sun, Y. (2022). Indoor microbiome and allergic diseases: From theoretical advances to prevention strategies. *Eco-Environment & Health*, 1(3), 133–146. <https://doi.org/10.1016/j.eehl.2022.09.002>
- [4] Lisik, D., Basna, R., Dinh, T., Hennig, C., Shah, S. A., Wennergren, G., Goksör, E., & Nwaru, B. I. (2024). Artificial intelligence in pediatric allergy research. *European Journal of Pediatrics*, 184(1). <https://doi.org/10.1007/s00431-024-05925-5>
- [5] Fu, D., Chuanliang, Z., Jingdong, Y., Yifei, M., Shiwang, T., Yue, Q., & Shaoqing, Y. (2023). Artificial intelligence applications in allergic rhinitis diagnosis: Focus on ensemble learning. *Asia Pacific Allergy*. <https://doi.org/10.5415/apallergy.0000000000000126>
- [6] *Classifying allergic rhinitis subjects and identifying single nucleotide polymorphisms using a support vector machine approach.* (n.d.).
- [7] Zhang, Y., Huang, Y., Chen, W., & Xu, Z. (2021). Identification of key genes in allergic rhinitis by bioinformatics analysis. *Journal of International Medical Research*, 49(7). <https://doi.org/10.1177/03000605211029521>
- [8] Aggelides, X., Bardoutsos, A., Nikolettseas, S., Papadopoulos, N., Raptopoulos, C., & Tzamalís, P. (2020, May 1). *A Gesture Recognition Approach to Classifying Allergic rhinitis gestures using wrist-worn devices : A multidisciplinary case study.* <https://doi.org/10.1109/dcoss49796.2020.00015>
- [9] Eckl-Dorna, J., Villazala-Merino, S., Campion, N. J., Byazrova, M., Filatov, A., Kudlay, D., Karsonova, A., Riabova, K., Khaitov, M., Karaulov, A., Niederberger-Leppin, V., & Valenta, R. (2019). Tracing IGE-Producing cells in allergic patients. *Cells*, 8(9), 994. <https://doi.org/10.3390/cells8090994>
- [10] Caimmi, D., Baiz, N., Sanyal, S., Banerjee, S., Demoly, P., & Annesi-Maesano, I. (2018). Discriminating severe seasonal allergic rhinitis. Results from a large nation-wide database. *PLoS ONE*, 13(11), e0207290. <https://doi.org/10.1371/journal.pone.0207290>
- [11] Che, Y., Wang, N., Ma, Q., Liu, J., Xu, Z., Li, Q., Wang, J., & Sun, Y. (2023). Microbial characterization of the nasal cavity in patients with allergic rhinitis and non-allergic rhinitis. *Frontiers in Cellular and Infection Microbiology*, 13. <https://doi.org/10.3389/fcimb.2023.1166389>
- [12] Yuan, Y., Wang, C., Wang, G., Guo, X., Jiang, S., Zuo, X., Wang, X., Hsu, A. C., Qi, M., & Wang, F. (2022). Airway Microbiome and serum metabolomics analysis identify differential candidate biomarkers in allergic rhinitis. *Frontiers in Immunology*, 12. <https://doi.org/10.3389/fimmu.2021.771136>
- [13] Panganiban, R. P., Wang, Y., Howrylak, J., Chinchilli, V. M., Craig, T. J., August, A., & Ishmael, F. T. (2016). Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma. *Journal of Allergy and Clinical Immunology*, 137(5), 1423–1432. <https://doi.org/10.1016/j.jaci.2016.01.029>
- [14] Zaigham, S., Bertelsen, R., Dharmage, S., Schlünssen, V., Jögi, N., Gomez, L. P., Holm, M., Oudin, A., Abramson, M., Sigsgaard, T., Jögi, R., Svanes, C., Olin, A., Forsberg, B., Janson, C., Nerpin, E., Johannessen, A., & Malinovschi, A. (2024). An observational analysis on the influence of parental allergic rhinitis, asthma and smoking on exhaled nitric oxide in offspring. *Nitric Oxide*, 149, 60–66. <https://doi.org/10.1016/j.niox.2024.06.001>
- [15] Sousa-Pinto, B., Vieira, R. J., Brozek, J., Cardoso-Fernandes, A., Lourenço-Silva, N., Ferreira-Da-Silva, R., Ferreira, A., Gil-Mata, S., Bedbrook, A., Klimek, L., Fonseca, J. A., Zuberbier, T., Schünemann, H. J., & Bousquet, J. (2024). Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis. *Journal of Allergy and Clinical Immunology*. <https://doi.org/10.1016/j.jaci.2024.04.016>
- [16] Larenas-Linnemann, D. E. S., Domthong, P., Di Francesco, R. C., González-Pérez, R., & Verma, M. (2024). General practitioner and patient perspectives on intranasal corticosteroids for allergic rhinitis: Treatment duration and obstacles to adherence, findings from a recent survey. *World Allergy Organization Journal*, 17(7), 100925. <https://doi.org/10.1016/j.waojou.2024.100925>

- [17] Vo-Thi-Kim, A., Van-Quang, T., Nguyen-Thanh, B., Dao-Van, D., & Duong-Quy, S. (2020). The effect of medical treatment on nasal exhaled nitric oxide (NO) in patients with persistent allergic rhinitis: A randomized control study. *Advances in Medical Sciences*, 65(1), 182–188. <https://doi.org/10.1016/j.advms.2019.12.004>
- [18] Bousquet, J., Klimek, L., Kuhl, H., Nguyen, D. T., Ramalingam, R. K., Canonica, G. W., & Berger, W. E. (2025). In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate. *World Allergy Organization Journal*, 18(1), 101021. <https://doi.org/10.1016/j.waojou.2024.101021>
- [19] Ridolo, E., Nicoletta, F., Lombardi, C., Passalacqua, G., Senna, G., & Canonica, G. W. (2024). Eosinophilic esophagitis and inhalant antigens: Pointing out the roles of allergic rhinitis, immunotherapy and biologic treatment. *World Allergy Organization Journal*, 17(10), 100968. <https://doi.org/10.1016/j.waojou.2024.100968>
- [20] Xu, X., Li, J., Zhang, X., Xi, L., Gao, Y., Li, X., Zhang, Y., & Zhang, L. (2024). Blood and local eosinophil levels in chronic rhinitis: Observations during seasonal allergen exposure and non-exposure. *World Allergy Organization Journal*, 17(7), 100930. <https://doi.org/10.1016/j.waojou.2024.100930>